US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Catalyst Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
News headline image
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
< Previous 1 2 3 Next >